|
 |
| home > pmps > winter 2003 > primary production of biopharmaceuticals in plants - an economically attractive choice? |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Plants as Alternative Eukaryotic Expression Systems
The progress of molecular plant genetics, and particularly of transgene expression in plants, has spurred the interest of academia and companies to consider them as eukaryotic hosts for biopharmaceutical production and as an additional or even alternative system to established mammalian cell culture (CHO) and yeast fermentation (1). Two arguments favouring plant hosts have frequently been quoted, namely safety - the absence of adventitious mammalian viral or prionic contamination - and the unlimited scalability of production.
Whether the future launch of biogenerics and the market introduction of numerous new therapeutic monoclonal antibodies will really be accompanied by a strong capacity shortage in primary production, as often predicted, is as yet uncertain. Therefore it is worthwhile to analyse whether plant expression systems have the potential to become an additional sourcing route for biopharmaceutical active ingredients in collaboration with, and as a feasible technological extension of, established mammalian cell culture and microbial fermentation.
From the viewpoint of the pharmaceutical industry, the prerequisites that a new expression system must fulfil are as follows:
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
7th Annual Pharma Packaging and Labelling conference
17 September - 18 October 2008, Barcelona
7th Annual Pharma Packaging and Labelling conference will bring
together experts from leading pharma manufacturers to present case study driven
presentations on critical industry-wide issues.
Attending this event will give you an opportunity to discuss with fellow
packaging and labelling professionals and share your views on these important
matters.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
